In this paper, we briefly review cancer proteomics in general, with particular attention to our proteome analyses of prostate cancer. Our efforts include development of new tools and novel approaches to discovering proteins potentially useful as cancer diagnostic and/or prognostic biomarkers or as therapeutic targets. To this end, we analyzed prostate cancer proteomes using twodimensional gel electrophoresis employing agarose gels for the initial isoelectric focusing step (agarose 2-DE), with mass spectrometry used for protein identification. Agarose 2-DE offers advantages over the more widely used immobilized pH gradient 2-DE for separating high molecular mass proteins (15-500 kDa), thereby increasing its power to detect changes in the cancer's high-molecular mass proteomes.
Introduction
The word 'proteome,' coined in 1994, designates the complete set of proteins that ultimately results from genome transcription in a given cell, tissue or organism. 1 Proteome analysis includes profiles of protein expression, which is complementary to mRNA profiling (transcriptome analysis). However, if we take the words in their broader sense, they do not merely mean protein profiling but analyses of the functional states of proteins, including activity, post-translational modifications, localization, and protein-protein, protein-ligand or proteinnucleic acid interactions. The proteome of a cell, tissue, or organism, like its transcriptome, depends dynamically on the state of the organism; proteomic studies can thus detect subtle changes in the organism's state between one time point and another.
Cancer proteomics is expected to reveal tumor-specific proteomes that correlate with clinical features and tumor progression. Such tumor-specific proteomes would provide clues to new biomarkers in serum and other biological fluids that could support early diagnosis. However, the large amount of information generated by proteomic tools such as two-dimensional gel electrophoresis (2-DE) and mass spectrometry (MS) calls for intensive analysis of the data in order to search for inventive cancer therapies and to support drug discovery.
The diagnosis and treatment of urological malignancies, including renal cell carcinoma, bladder cancer, and prostate cancer, remains in a rather rudimentary state. All these cancers exhibit few symptoms in their early stages. Yet once they have grown significantly in size and reached more advanced stages, few effective therapies are available. This unsatisfactory state of affairs encourages us to adopt proteomic approaches both as a means toward finding novel biomarker proteins specifically expressed in early stages of these malignancies and as an aid in understanding the molecular mechanisms of tumor progression.
In this article, we shall present a brief review of our progress in applying 2-DE-based proteomics to the study of prostate cancer, including our development of unique tools and approaches to discovering proteins that may serve as diagnostic and/or prognostic biomarkers or as therapeutic targets.
Proteome analysis
Proteomes can be analyzed either by using initial 2-DE or with gel-free methods (Figure 1 ). High-resolution 2-DE provides a powerful method for reproducible separation, visualization, and quantitation of thousands of proteins on a single gel. 2 The popular 2-DE method originally developed by O'Farrell 3 in 1974 utilizes a polyacrylamide gel in both dimensions. Proteins are separated by isoelectric focusing (IEF) in the first dimension, using an immobilized pH gradient (IPG) polyacrylamide gel, and according to molecular weight by sodium dodecyl sulfate (SDS) electrophoresis in the second dimension.
Although 2-DE has been a mature technique for almost 30 years, its application in proteomics had to wait for development of MS and a genomic sequence database. The technology of MS has made great progress during the 1990 s and has now attained femtomolar sensitivity, making it possible to identify almost any protein spot separated by 2-DE and visualized by Coomassie brilliant blue staining. 4 Since a mass spectrometer measures the mass-to-charge ratio (m/z) of the ionized analytes, ionization techniques are very important. There are chiefly two ionization methods: electrospray ionization (ESI) and matrix-assisted laser desorption/ionization (MALDI). These techniques have solved the difficult problem of generating ions from nonvolatile analytes such as proteins and peptides without significant analyte fragmentation. The identifying m/z of ionized analytes can be measured by mass analyzers, of which there are four basic types: the ion trap, the time-of-flight (TOF), the quadrupole, and the Fourier transform ion cyclotron (FT-MS) analysers. Mass spectrometric data can be correlated with those in sequence databases using any of several search algorithms, most of which are available on the World Wide Web. We commonly use two different approaches for identification of proteins: peptide-mass mapping by MALDI-TOF and peptide sequencing by electrospray ionization-tandem mass spectrometry (ESI-MS/MS). In peptide-mass mapping, proteins are identified, after proteolysis with a protease that breaks specific peptide bonds, by matching a list of experimental peptide masses with the calculated list of all peptide masses for each entry in a comprehensive protein database. In peptide sequencing, a peptide ion is fragmented in a collision cell by a process called collision-induced dissociation (CID), and the fragment ion spectrum is recorded. The CID spectra provide information about peptide sequences. Used in combination with the peptide mass, protein identifications using peptide CID spectra are more clearcut than those achieved by mass mapping. 5 Although a combination of 2-DE and MS remains the most common approach, new proteomic tools that do not depend on 2-DE are rapidly being developed. Multidimensional protein identification technology (MudPIT) -so-called 'shot-gun proteomics'-provides direct comprehensive analysis of complex protein mixtures. This approach incorporates multidimensional highperformance liquid chromatography (HPLC), ESI-MS/ MS, and database searching algorithms. 6 Multidimensional HPLC was proposed more than a decade ago as a way to separate proteins and peptides, with the past few years having seen development of highly effective methods for peptide separation. An example is nanoflow capillary reverse-phase liquid chromatography (cRPLC)-ESI-MS/ MS, in which separation of complex digested protein mixtures by nanoflow cRPLC is followed immediately by online mass spectroscopic detection using automated acquisition modes that allow conventional MS and MS/ MS spectra to be collected in a data-dependent manner. As with 2-DE methods, automated data processing and database searching then identify the parent proteins.
MALDI enables to identify and characterize the primary structural features of proteins. Several researchers reported protein profiles in sera of patients. Ferrari et al 7 examined the sera of patients with malignant cutaneous melanoma to study changes occurring in protein profiles during the course of the disease and to verify the clinical usefulness of the detection of serum protein alterations. They showed the differences between the MALDI spectra from sera of healthy controls and patients. Direct MALDI analysis of clinical samples looks promising as diagnostic method.
There are also promising new techniques for functional proteomics. Protein array technology is finding its way into quantitative proteomics, much as DNA array technology is doing in other areas. A protein array comprises many different affinity reagents (frequently antibodies) arrayed at high spatial density on a solid support. Each agent captures its target protein from a complex mixture (such as serum or a cell lysate), and the captured proteins are subsequently detected and quantified. 8 Although originally fluorescent dyes were applied for differential display of binding to a protein array, advancing MS technologies have allowed new approaches. One of these is surface enhanced laser desorption/ionization (SELDI)-TOF MS, 9 which is often Another approach used for functional proteomics is isotope tagging. A successful, commercially available example is isotope-coded affinity tags (ICAT), which are used to detect differences between control and treated samples separated by either gel-free proteomic or 2-DEbased methods. 11 ICAT reagents reacting with cysteine residues are either labeled (d8) or not labeled (d0) with deuterium atoms. The two samples are treated with ICAT reagents of different isotopic weighs, after which the proteins are separated by multidimensional HPLC or 2-DE. On identifying the various proteins by MS and MS/MS, the relative signal intensities of isotopically light and heavy ICAT-tagged peptides quantify differences in protein expression between the two samples. 12 So far, various forms of isotope-tagging chemistry have been employed as powerful tools for analyzing post-translational modifications at sulphydryl groups, amino groups, the active sites of serine and cysteine hydrolases, phosphate ester groups, and N-linked carbohydrases. 5 These isotope-tagging approaches are promising tools for functional proteomics.
We have applied 2-DE-based proteomics using combined cRPLC-ESI-MS/MS for protein identification. Briefly, our proteomic approach utilizes the following steps:
(1) Proteins in the mixture are separated by 2-DE ( Figure 1 ) employing an agarose gel for the initial isoelectric focusing step (agarose 2-DE). Agarose 2-DE is superior to the widely used IPG 2-DE for separating high-molecular mass proteins as large as 500 kDa.
(2) Following visualization of the separated proteins using Coomassie blue, spots are cut out and the protein in the gel piece is digested with trypsin.
(3) Digested peptide fragments are allowed to diffuse out of the gel into a surrounding buffer solution. The solubilized peptide mixture is then fractionated by cRPLC, after which the protein is identified by ESI-MS. The mass spectrometer automatically measures the MS and MS/MS spectra of each peptide in succession. Each peptide is sorted and weighed in the first mass spectrometer, then broken into fragments in a collision cell and each fragment sorted and weighed in the second mass spectrometer. These masses are displayed graphically with m/z as the abscissa and relative abundance as the ordinate axis.
(4) Computer analysis of the MS and MS/MS spectra makes it possible to infer the peptide's amino-acid sequence and, hence, identify the protein. 13, 14 In our research, we used the computer software SEQUEST, available for download at http://fields.scripps.edu/ sequest/index.html. This software carries out the entire process of protein identification almost automatically, with little human intervention needed.
There are two requirements for effective 2-DE-based proteomics: the full array of proteins in a tissue or group of cells must be well separated and displayed as distinct spots in the 2-DE gel, and each protein spot must include enough protein for MS/MS identification. We chose agarose 2-DE as the method best fulfilling these requirements. Agarose 2-DE covers a wide range of protein isoelectric points (pI 3-10) and molecular masses (15-500 kDa). Furthermore, the gel can be loaded with as much as 1.5 mg of protein, which is more than enough for identification of the separated proteins. 15 However, all 2-DE-based proteomic methods experience reproducibility problems that make it difficult to accurately match protein spots in different gels. The reproducibility of conventional 2-DE can be improved using differential in-gel electrophoresis (DIGE), a newly emerging technology for proteomic analysis. 16 In DIGE, two pools of proteins are labeled with different fluorescent cyanine dyes, such as Cy3 and Cy5, and the labeled proteins are mixed and separated in the same gel slab. A comparison of the resulting images allows quantitation of each protein spot. As two protein pools are separated in the same gel, proteins found in both pools will migrate to the same gel locations, thus minimizing the reproducibility problem.
Agarose 2-DE has several advantages but its reproducibility is a little inferior to IPG-based 2-DE, because carrier ampholite is not immobilized in the first dimensional agarose IEF gel. Use of 2D-DIGE in combination with the agarose 2-DE allow us to quantitatively compare two 2-DE patterns. Proteomics based on agarose 2D-DIGE thus provides both the high reproducibility of DIGE technology and the ability of agarose 2-DE to separate high molecular mass proteins. The results of 2-DE gel image analyses and peptide sequence data are stored together in a database for further examination.
As described, proteomics is expanding. However, success in proteomics depends upon the ability to effectively and accurately analyze the highly multidimensional data in a rapid and high-throughput manner. The previous achievements of genomics, which provided the blueprint of possible gene products representing the focal point of proteomics studies, has led to establishment of a huge protein database. The significance of bioinformatics in proteomics will increase even more with the development of automated highthroughput methods relying on powerful data analysis. Bioinformatics is going to play a bigger role in proteomics and provide new ideas for correlations of protein sequence, structure, function, regulation, expression and modification. The trick to analyzing high molecular mass protein lies in the use of agarose gel instead of polyacrylamide gel for the first-dimensional IEF. This method was initially described by Hirabayashi in 1981; 18 we have continued to develop it thereafter. Details of the procedure are described in our earlier reports. 15, 19 At this time, agarose 2-DE is the only way to separate proteins with masses up to 500 kDa.
Proteomic approaches for prostate cancer
Prostate cancer is the most common cancer and the second leading cause of cancer-related death among men of Western countries. 20 Since most prostate cancers show few symptoms in their early stages, the disease is often diagnosed in an advanced stage. Prostate-specific antigen (PSA) has proven a useful biomarker for the detection of cancer, but PSA in the 'gray zone' from 4 to 10 ng/ml is limited in its ability to differentiate prostate cancer from benign prostate hyperplasia (BPH); specificity of the test is only 25-30%. 21, 22 Furthermore, Crawford et al 23 reported little correlation between declines in PSA level and decrease in tumor growth or grade. These limitations of the PSA test call for further efforts toward discovery of biomarkers more effective for diagnosis and prognosis of prostate cancer.
Researchers have been utilizing proteomic approaches for this purpose. The conventional 2-DE technique has been applied to samples from patients with prostate cancer that include prostatic fluid, urine, the nuclear matrix, and cell lysates. The prostatic fluid contained an unknown constituent named protein D that was found exclusively in patients with prostate cancer. This protein had a molecular mass of about 22 kDa and an isoelectric point of pI 4. 24 Urine was found to contain several markers of potential clinical usefulness, among which two were downregulated and another two overexpressed in prostate cancer patients. 25 A 2-DE analysis of nuclear matrix proteins from prostatic tissues found 14 proteins that differed in amount among extracts of normal, BPH, and prostate cancer specimens. 26 Lack of advanced MS techniques at the time prevented identification of these proteins.
A recent 2-DE-based analysis of surgical prostate cancer specimens found that they contained significantly increased levels of proliferating cell nuclear antigen (PCNA), calreticulin, heat shock protein (HSP) 90, HSP 60, oncoprotein 18(v), elongation factor 2, glutathione-Stransferase pi (GST-pi), superoxide dismutase, and triose phosphate isomerase. 27 This study also reported lower amounts of tropomyosin-1 and -2 and cytokeratin 18 in prostate cancer than in BPH. The same group reported in a subsequent study that 23 proteins out of 800 were somewhat different in amount between BPH and prostate cancer specimens. 28 The more recent gel-free proteomics approach has also been used to search for new biomarkers. Using SELDI-TOF MS, Xiao et al 29 gathered data that identifies prostate cancer with better specificity and selectivity than PSA. For example, they used the ProteinChip immunoassay to detect and quantify prostate-specific membrane antigen (PSMA), making it possible to discriminate between benign and malignant prostate disease. The other significant property of SELDI is its ability to provide comprehensive and high-throughput analysis. Cazares et al 30 reported the utility of combined analysis of two or more lysate proteins for distinguishing benign from nonbenign cells in microdissected prostatic tissue. The combination of two specific protein peaks improved the cancer-detection sensitivity to 100% while maintaining 87% specificity. When they incorporated the seven most significant differentially expressed proteins in a logistic regression analysis, a predictive equation resulted that gave 93.3% specificity and 93.8% sensitivity for nonbenign cells.
While target proteins have not been identified, pattern analysis of MS spectra may be a promising method to screen cancer patients. For example, Petricoin III et al 31 found that serum MS spectrum patterns predicted the presence of cancer more precisely than did serum PSA value.
Other researchers have tried several methods of processing the flood of MS data to make it more clinically applicable, with a decision tree algorithm being among the more popular approaches. Adam et al 32 built a decision tree algorithm with representative MS spectra of sera from patients and controls. Using an algorithm based on nine protein peaks from the serum sample, they detected prostate cancer with 83% sensitivity and 97% specificity. Moreover, advanced bioinformatics learning algorithms have been applied in an analysis of SELDI data. Qu et al 33 developed two boosted decision tree algorithms for analyzing multiple computer-detected peaks in serum SELDI data. One of them was the AdaBoost classifier, the other was the Boosted Decision Stump Feature Selection (BDSFS) classifier. Although the former produced 100% sensitivity and specificity, it used 74 protein mass peaks and required combining 500 base decision tree classifiers, making it difficult to interpret. The latter was easier to interpret, using only 21 peaks and a combination of 21 base classifiers; this algorithm achieved a sensitivity and specificity of 97% in identifying patients with cancer. This study demonstrated the potential of SELDI when coupled with development of learning algorithms.
The combination of several types of ProteinChip array is also a promising strategy. Banez et al 34 analyzed sera from prostate cancer patients and controls with two types of ProteinChip arrays: the weak cation exchange array and the copper metal affinity capture array. Combined spectral data from the two types of array were used to generate a decision tree algorithm that used only three protein peaks but achieved 85% sensitivity and 85% specificity for prostate cancer detection. These studies based on SELDI suggest that it is not necessary to identify protein peaks to make a diagnosis.
With the application of ICAT, Griffin et al 35 reported differences in expressed proteins between nontumorigenic and cancerous human prostate epithelial cells. Since this technique is one of the high-throughput approaches to quantitative proteomic analysis, it is a promising tool in the search for novel biomarkers of prostate cancer.
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Combined analyses of the cancer transcriptome and proteome have also been successful. Expressed sequence tags (ESTs) and full-length cDNA sequences are maintained in a database, the Prostate Expression Database (PEDB) at http://www.mbt.washington.edu/PEDB/. 36 The transcriptomic approach detected 20 androgenregulated genes, while proteomic analysis provided protein expression profiles of androgen-regulated prostate cancer. 37 Using agarose 2-DE, we analyzed androgen independent prostate cancer using xenograft models of the human prostate cancer cell line LNCaP. LNCaP cells were inoculated by subcutaneous injection in the flank region of 10 male athymic nude mice. Half of the mice bearing tumors were castrated via a scrotal or abdominal approach under ether anesthesia. The tumors shrank temporally, but in a little while, surviving cancer cells became independent of androgens to be able to proliferate in the castrated mice. Androgen-dependent (AD) or -independent (AI) tumors are those extirpated from noncastrated or castrated mice, respectively. Five sets of AD and AI tumor lysates were at least twice analyzed with agarose 2-DE loaded 1.0 mg proteins to give reproducible proteomes. To separate proteins into broad mass ranges, we prepared two types of polyacrylamide gels for use in the second dimension, one with a homogenous 12% polyacrylamide concentration and the other with a linear 6-10% gradient. About 500 protein spots could be seen on a 2-DE gel stained with Coomassie brilliant blue. Figure 2 shows agarose 2-DE gel-maps of LNCaP. The numbers shown on the figure are the protein-spot numbers (PNs). PN 001-108 are high molecular mass proteins excised from the 6-10% gel, while the rest (PN 109-303) were excised from the 12% gel. Of 303 spots, 275 (90.8%) were identified as named proteins using cRPLC-ESI-MS/MS and computed database searching with program SEQUEST as described. Since mouse serum proteins might be contaminated in the tumors, we used both human and murine protein databases. Human protein candidates having higher SEQUEST scores were expected to be the protein we looked for. Excluding redundant proteins in several spots and mouse-serum proteins, we considered the remaining 225 proteins to be cancer-related in this study. The highest and lowest protein molecular masses found in this study were 518 kDa for plectin 1 (PN 003) and 15.9 kDa for superoxide dismutase 1 (PN 294), respectively. We divided the 225 cancer-related proteins into high molecular mass and low molecular mass groups using a rather arbitrary cutoff value of 80 kDa. The former group contained 84 high molecular mass proteins and the latter 141 low molecular mass ones.
When the tumor progressed from the androgendependent to androgen-independent state, 11 proteins among the 225 cancer-related ones changed significantly in content (Po0.05, Figure 1 ). We successfully identified eight of them. Of these, five were found to be upregulated and three were downregulated at the transition to androgen independence ( Table 1) homolog are considered to be translation initiation factors. Antioxidant protein 2 protects cells from oxidant stress. ATP synthase beta chain is essential for energy metabolism and cofilin 1 binds actin and assists translocation of actin from the cytoplasm to the nucleus. Scaffold attachment factor B acts as an estrogen receptor corepressor, and spliceosome-associated protein 130 gathers spliceosomes to splice RNAs. The function of ha1225 gene product is unknown. In these eight proteins, only cofilin 1 had been known to be related with prostate cancer. 38 The connection of the other proteins with prostate cancer was considered novel. It should be noted that we could not find any well-known biomarkers such as PSA, PSMA, p53, p27, Bcl-2, Ki-67, E-cadherin and so on, 39 which had been found by genomic approaches. We consider the discrepancies were caused by the following reason: several reports told that correlation between mRNA and protein levels was insufficient to predict protein expression levels from quantitative mRNA data. 40, 41 The proteomic approach is considered to have a capability of finding biomarkers other than those found by genomic approach.
We stratified the cancer-related proteins into seven functional categories based on the prostate expression database (PEDB). 36 These categories were cell division, cell signaling/communication, cell structure/motility, cell/organism defense, gene/protein expression, metabolism, and unclassified. Figure 3 shows pie charts of the functional classification of total proteins (left), high molecular mass proteins (center), and low molecular mass proteins (right). The gene/protein expression group, which includes translation factors, DNA or RNA binding proteins, elongation factors, ribosomal proteins, and so on, accounted for 38.5% of the 225 cancer-related proteins. This was followed by the metabolism group, representing 23.5%. Proteins belonging to the cell signaling/communication, cell structure/ motility, and cell/organism defense groups were almost equally represented, accounting for 10.6, 9.7 and 11.5%, respectively, of the total proteins. In the eight candidate proteins, half of them belonged to the gene/protein expression group, including hnRNP homolog JKTBP, William-Beuren syndrome chromosome region 1 homolog, scaffold attachment factor B and spliceosomeassociated protein 130 (Table 1) . Importance of the gene/protein expression group in the candidates suggested that the group were keys in androgen-independent progression of prostate cancer.
It is clear that the various functional classes are differently represented among proteins of high and low molecular mass: more than half (54.1%) of the high molecular mass proteins but less than one-third (29.1%) of the low molecular mass ones were classified as transcription/translation-related proteins. Metabolismrelated proteins occupied the second biggest proportion (29.8%) in the high molecular mass group. This result suggests that high molecular mass proteins have important roles in cancer progression. 
We have recently applied agarose-2D-DIGE to analysis of high molecular mass proteins. This allowed us to see clear differences in the 2-DE patterns from extracts of androgen-dependent and -independent prostate cancer cells including changes in the amounts of several proteins larger than 80 kDa. In Figure 4 , red spots indicate proteins that are upregulated and green ones those that are downregulated as the cancer changes from the androgen-dependent to the androgen-independent state. Identification of these proteins is now underway, and the resulting data will be useful for inferring the mechanism by which prostate cancers acquire androgen independence.
Conclusions
Development of proteomic techniques for studying prostate cancer offers great potential for discovery of novel biomarkers and identification of new therapeutic agents. Gel-free proteomics, including isotope-tag, Mud-PIT and protein array, are promising in its high throughput capabilities and automated applications, but are hard to identify candidate proteins. 2-DE-based proteomics, on the other hand, has advantages in identification. Although several candidates have been detected with conventional 2-DE, most of them have not yet proven clinically useful. We applied a unique agarose 2-DE method to the analysis of prostate cancer cells. This technique, which had advantages in analyzing high molecular mass proteins and achieving high identification rate, contributed to our finding new candidates of androgen-independent markers. It is doubtless that further development of various proteomic tools would expand the breakthrough in cancer research.
